Skip to main content
Oryzon Genomics S.A. logo

Oryzon Genomics S.A. — Investor Relations & Filings

Ticker · ORY ISIN · ES0167733015 LEI · 95980063R15RDF29DK13 MC Manufacturing
Open in API
Filings indexed 142 across all filing types
Latest filing 2020-06-25 Share Issue/Capital Cha…
Country ES Spain
Listing MC ORY

About Oryzon Genomics S.A.

https://www.oryzon.com/en

Oryzon Genomics is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on epigenetics. The company's primary focus is on creating personalized medicines for patients with cancer and central nervous system (CNS) disorders. Utilizing a proprietary epigenetic platform, Oryzon identifies and validates biomarkers and therapeutic targets to advance its pipeline of potential treatments. The company's therapeutic programs aim to address diseases with significant unmet medical needs by regulating gene expression without altering the underlying genetic sequence.

Recent filings

Filing Released Lang Actions
La compañía anuncia una ampliación de capital mediante una colocación privada
Share Issue/Capital Change Classification · 98% confidence The document is an official communication from ORYZON GENOMICS, S.A. titled "INFORMACIÓN PRIVILEGIADA" (Inside Information) announcing a resolution by the Board of Directors to increase the share capital ("Aumento de Capital") through the issuance of new shares, specifically excluding the pre-emptive subscription right. It details the amount, price, placement procedure (private placement to qualified investors), and the purpose (financing R&D and potential dual listing on Nasdaq). Crucially, the document explicitly states that the justification for excluding the pre-emptive right is contained in an attached document: "ANEXO I" (Informe de Administradores). Furthermore, the text includes the beginning of the "INFORME DEL CONSEJO DE ADMINISTRACIÓN... EN RELACIÓN CON LA PROPUESTA DE ACUERDO DE AUMENTO DE CAPITAL CON EXCLUSIÓN DEL DERECHO DE SUSCRIPCIÓN PREFERENTE". This structure—an announcement detailing a financing action and referencing an attached detailed report justifying the action—is characteristic of a Capital/Financing Update (CAP). It is not a general regulatory filing (RNS) because it is highly specific, nor is it a Report Publication Announcement (RPA) because it contains the core details of the financing event itself, rather than just announcing the publication of a separate report.
2020-06-25 Spanish
ORYZON presenta datos positivos de eficacia de iadademstat de su ensayo clínico de Fase IIa en marcha en leucemia mieloide aguda en la conferencia EHA-2020
Earnings Release Classification · 99% confidence The document is titled as an 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) communication, mandated by Spanish securities law (article 227 of the Consolidated Text of the Securities Market Law). It announces that ORYZON is presenting new positive efficacy data for its drug iadademstat at the EHA-2020 Congress. The text includes a summary of the results, quotes from the CEO, and details about the clinical trial (ALICE). Crucially, it mentions that a press release summarizing these results is attached and distributed today, and it provides a link to the actual poster presented at the conference. This structure—a brief regulatory filing announcing the release of detailed scientific/clinical data—fits the definition of a Report Publication Announcement (RPA), as it is primarily an announcement about the publication of results elsewhere (the EHA conference poster/press release), rather than the full, comprehensive report itself (like an ER or IR). The document length (9756 chars) is substantial, but its function is clearly to disseminate the news of the presentation, making RPA the most accurate classification based on the provided definitions, especially considering the 'MENU VS MEAL' rule context where announcements of reports are distinct from the reports themselves. FY 2020
2020-06-12 Spanish
ORYZON remite nota de prensa en relación a la composición de su Consejo de Administración
Board/Management Information Classification · 99% confidence The document is an official communication ("OTRA INFORMACIÓN RELEVANTE") from ORYZON GENOMICS, S.A., dated May 11, 2020, announcing a change in its Board of Directors. Specifically, it details the incorporation of Dr. Manuel López Figueroa and the departure of Dr. Vanessa Almendro Navarro due to professional incompatibility. This content directly matches the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2020-05-11 Spanish
El fármaco VAFIDEMSTAT de Oryzon Genomics S.A. recibe la aprobación para llevar a cabo un ensayo clínico de Fase II con enfermos graves de COVID-19, por parte de la Agencia Española del Medicamento y
Regulatory Filings Classification · 95% confidence The document is a formal communication from ORYZON GENOMICS, S.A. to the market, identified by the header "OTRA INFORMACIÓN RELEVANTE" (Other Relevant Information) and referencing Spanish securities law (art. 227 of the Consolidated Text of the Securities Market Law). The core content announces that the company received approval from the Spanish Agency of Medicines and Medical Devices (AEMPS) to start a Phase II clinical trial (ESCAPE study) for their drug vafidemstat in severe COVID-19 patients. It includes a press release detailing the scientific rationale and next steps. This type of announcement, which communicates material, non-public information regarding clinical trial progress or regulatory milestones, is typically classified as a general regulatory announcement or a specific update related to corporate/product development. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it is a specific, material update often disseminated via regulatory channels, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a mandatory disclosure of a significant event. It is not a proxy statement (DEF 14A), director dealing (DIRS), or capital change (CAP). Given the nature of the announcement (regulatory approval for a clinical trial), RNS is the most appropriate catch-all for significant, non-financial, non-management-change disclosures.
2020-04-24 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is titled 'STANDARD FORM FOR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM'. This form explicitly deals with transactions (share dealings) conducted by directors or senior management (PDMRs). This directly corresponds to the definition for Director's Dealing (DIRS), which covers 'Report of personal share transactions by company directors and executives (insider trades)'. The document details the PDMR (VANESSA ALMENDRO NAVARRO), her position (CONSEJERA - Director), and the transaction details, confirming the classification.
2020-04-23 Spanish
ORYZON remite nota de prensa relativa a los planes de contingencia implementados por la Sociedad en relación con la pandemia de COVID-19
Regulatory Filings Classification · 95% confidence The document is a formal communication from ORYZON GENOMICS, S.A., dated April 17, 2020, filed under Spanish securities law (article 227 of the Consolidated Text of the Securities Market Law). The title is "ORYZON informa sobre sus planes de contingencia frente a la pandemia de COVID-19" (ORYZON reports on its contingency plans regarding the COVID-19 pandemic). It details operational changes, clinical trial adjustments, and business continuity measures. Crucially, the introductory paragraph states: "ORYZON remite nota de prensa relativa a los planes de contingencia implementados por la Sociedad en relación con la pandemia de COVID-19, que se adjunta a la presente." (ORYZON sends a press release regarding the contingency plans implemented by the Company in relation to the COVID-19 pandemic, which is attached hereto.) This structure—a brief announcement stating that a press release/information is attached or being sent—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), rather than the full content of a specific report like an Earnings Release (ER) or Interim Report (IR). Since it is a specific announcement about publishing information (a press release on contingency plans), RPA is the most precise fit, as it signals the publication of material information. If the document were the full, detailed contingency plan itself, it might fit under LTR (Legal/Regulatory updates) or RNS (General Regulatory Filing). However, the explicit mention of sending/attaching the 'nota de prensa' strongly suggests this filing is the mechanism of publication.
2020-04-17 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.